AlphaValue Corporate Services Fundamental Analysis FR
Back to
AlphaValue Corporate Services

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
The market is within reach
Updates
29/11/18 TargetOur target price is revised downward on t...
29/11/18 EPSOur forecasts have not changed. The hig...
29/11/18 NAVOur NAV valuation is adjusted one the on...
29/11/18 DCFOur forecasts remain unchanged. The hig...
28/11/18 Financing i...A €3.9m capital increase
22/11/18 LatestExcellent news: production has resumed
23/10/18 Other newsBond conversion
03/10/18 EPSOur EPS forecasts only move marginally i...
03/10/18 NAVOur SOTP valuation goes down in line wit...
03/10/18 DCFOur DCF valuation goes quite substantial...
27/09/18 EarningsH1 18: insignificant; some more time nee...
05/09/18 EPSWe have fine-tuned our numbers in the b...
05/09/18 NAVWe have adjusted our numbers to take in...
05/09/18 DCFOur DCF valuation goes up quite signific...
13/07/18 Financing i...A convertible bond and potential options f...
17/05/18 LatestBusiness update
22/03/18 EarningsOn its way to reach the market…
14/02/18 Financing i...A convertible bond and options for existin...
03/02/18 Other newsOrphan disease status for Zeneo® Midaz...
11/12/17 Other newsUpdate on the company’s activities
25/09/17 EarningsH1 17: a new NTE in the pipeline...and fu...
06/04/17 Financing i...The capital increase was successful
14/03/17 EPSWe have not changed our assumptions a...
14/03/17 NAVThe SOTP valuation is only down on the ...
14/03/17 DCFOur DCF goes down on the increased nu...
13/03/17 EarningsFY16 results - untelling (as expected) an...
24/11/16 TargetOur target price goes down, mainly due t...
24/11/16 EPSOur EPS goes marginally down for FY17,...
24/11/16 NAVOur SOTP valuation also goes down, sin...
24/11/16 DCFWe have revised our forecasts, based on ...
23/11/16 StrategyA strategic review….and a few questions
20/09/16 EarningsH1 16 results: not very telling as expected
29/08/16 Other newsWhen apparent threats are also opportuni...
25/02/16 Initiating coverage of Crossject.
Target
Upside 753%
Price (€) 1.30
Market Cap (€M) 12.0
Perf. 1W: 2.86%
Perf. 1M: -2.45%
Perf. 3M: -56.5%
Perf Ytd: -71.1%
10 day relative perf. to stoxx600: -22.4%
20 day relative perf. to stoxx600: 8.49%
Overview
Value
Equity Risk
Governance
Ranking
Best
Crossject
Pharma
Worst